Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310856717> ?p ?o ?g. }
- W4310856717 endingPage "109521" @default.
- W4310856717 startingPage "109521" @default.
- W4310856717 abstract "In clinical practice, major efforts are underway to identify appropriate drug combinations to boost anticancer activity while suppressing unwanted adverse effects. In this regard, we evaluated the efficacy of combination treatment with the widely used chemotherapeutic drug doxorubicin along with the TGFβRI inhibitor galunisertib (LY2157299) in aggressive B-cell non-Hodgkin lymphoma (B-NHL). The antiproliferative effects of these drugs as single agents or in combination against several B-NHL cell lines and the synergism of the drug combination were evaluated by calculating the combination index. To understand the putative molecular mechanism of drug synergism, the TGF-β and stress signaling pathways were analyzed after combination treatment. An aggressive lymphoma model was used to evaluate the anticancer activity and post-therapeutic immune response of the drug combination in vivo. Galunisertib sensitized various B-NHL cells to doxorubicin and in combination synergistically increased apoptosis. The antitumor activity of the drug combinations involved upregulation of p-P38 MAPK and inhibition of the TGF-β/Smad2/3 and PI3K/AKT signaling pathways. Combined drug treatment significantly reduced tumor growth and enhanced survival, indicating that the synergism between galunisertib and Dox observed in vitro was most likely retained in vivo. Based on the tumor-draining lymph node analysis, combination therapy results in better prognosis, including disappearance of disease-exacerbating regulatory T cells and prevention of CD8+ T-cell exhaustion by downregulating MDSCs. Galunisertib synergistically potentiates the doxorubicin-mediated antitumor effect without aggravating the toxic effects and the ability to kickstart the immune system, supporting the clinical relevance of targeting TGF-βRI in combination with doxorubicin against lymphoma." @default.
- W4310856717 created "2022-12-19" @default.
- W4310856717 creator A5007670575 @default.
- W4310856717 creator A5030604244 @default.
- W4310856717 creator A5036463162 @default.
- W4310856717 creator A5055708314 @default.
- W4310856717 creator A5066525132 @default.
- W4310856717 creator A5075095640 @default.
- W4310856717 creator A5076860087 @default.
- W4310856717 date "2023-01-01" @default.
- W4310856717 modified "2023-10-15" @default.
- W4310856717 title "Galunisertib synergistically potentiates the doxorubicin-mediated antitumor effect and kickstarts the immune system against aggressive lymphoma" @default.
- W4310856717 cites W1492716968 @default.
- W4310856717 cites W1546466517 @default.
- W4310856717 cites W1579001322 @default.
- W4310856717 cites W1642873092 @default.
- W4310856717 cites W1982160989 @default.
- W4310856717 cites W2011118089 @default.
- W4310856717 cites W2025132904 @default.
- W4310856717 cites W2050115670 @default.
- W4310856717 cites W2058015212 @default.
- W4310856717 cites W2066118264 @default.
- W4310856717 cites W2082104827 @default.
- W4310856717 cites W2085309730 @default.
- W4310856717 cites W2096439168 @default.
- W4310856717 cites W2142153200 @default.
- W4310856717 cites W2143145234 @default.
- W4310856717 cites W2146000655 @default.
- W4310856717 cites W2171356556 @default.
- W4310856717 cites W2344682920 @default.
- W4310856717 cites W2523088287 @default.
- W4310856717 cites W2744261860 @default.
- W4310856717 cites W2774112395 @default.
- W4310856717 cites W2886504441 @default.
- W4310856717 cites W2895521914 @default.
- W4310856717 cites W2917526860 @default.
- W4310856717 cites W2929514848 @default.
- W4310856717 cites W2937823726 @default.
- W4310856717 cites W2992700277 @default.
- W4310856717 cites W2995796904 @default.
- W4310856717 cites W2998969077 @default.
- W4310856717 cites W3009142496 @default.
- W4310856717 cites W3031233770 @default.
- W4310856717 cites W3044737312 @default.
- W4310856717 cites W3091042718 @default.
- W4310856717 cites W3124370821 @default.
- W4310856717 cites W3146786433 @default.
- W4310856717 cites W3150423209 @default.
- W4310856717 cites W3159127675 @default.
- W4310856717 cites W3179729127 @default.
- W4310856717 cites W4206841660 @default.
- W4310856717 cites W4212971766 @default.
- W4310856717 cites W4220751606 @default.
- W4310856717 cites W4225845158 @default.
- W4310856717 cites W4293860912 @default.
- W4310856717 cites W4297573698 @default.
- W4310856717 doi "https://doi.org/10.1016/j.intimp.2022.109521" @default.
- W4310856717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36470118" @default.
- W4310856717 hasPublicationYear "2023" @default.
- W4310856717 type Work @default.
- W4310856717 citedByCount "2" @default.
- W4310856717 countsByYear W43108567172023 @default.
- W4310856717 crossrefType "journal-article" @default.
- W4310856717 hasAuthorship W4310856717A5007670575 @default.
- W4310856717 hasAuthorship W4310856717A5030604244 @default.
- W4310856717 hasAuthorship W4310856717A5036463162 @default.
- W4310856717 hasAuthorship W4310856717A5055708314 @default.
- W4310856717 hasAuthorship W4310856717A5066525132 @default.
- W4310856717 hasAuthorship W4310856717A5075095640 @default.
- W4310856717 hasAuthorship W4310856717A5076860087 @default.
- W4310856717 hasConcept C126322002 @default.
- W4310856717 hasConcept C150903083 @default.
- W4310856717 hasConcept C203014093 @default.
- W4310856717 hasConcept C207001950 @default.
- W4310856717 hasConcept C2776694085 @default.
- W4310856717 hasConcept C2776999253 @default.
- W4310856717 hasConcept C2779338263 @default.
- W4310856717 hasConcept C2781303535 @default.
- W4310856717 hasConcept C502942594 @default.
- W4310856717 hasConcept C71924100 @default.
- W4310856717 hasConcept C86803240 @default.
- W4310856717 hasConcept C8891405 @default.
- W4310856717 hasConcept C98274493 @default.
- W4310856717 hasConceptScore W4310856717C126322002 @default.
- W4310856717 hasConceptScore W4310856717C150903083 @default.
- W4310856717 hasConceptScore W4310856717C203014093 @default.
- W4310856717 hasConceptScore W4310856717C207001950 @default.
- W4310856717 hasConceptScore W4310856717C2776694085 @default.
- W4310856717 hasConceptScore W4310856717C2776999253 @default.
- W4310856717 hasConceptScore W4310856717C2779338263 @default.
- W4310856717 hasConceptScore W4310856717C2781303535 @default.
- W4310856717 hasConceptScore W4310856717C502942594 @default.
- W4310856717 hasConceptScore W4310856717C71924100 @default.
- W4310856717 hasConceptScore W4310856717C86803240 @default.
- W4310856717 hasConceptScore W4310856717C8891405 @default.
- W4310856717 hasConceptScore W4310856717C98274493 @default.
- W4310856717 hasFunder F4320320719 @default.
- W4310856717 hasFunder F4320320721 @default.